Enantioselectivity in antitumor activity of flavone derivatives
DOI:
https://doi.org/10.48797/sl.2026.460Keywords:
PosterAbstract
Background: Nature represents a rich source of bioactive compounds, with flavones standing out as privileged scaffolds owing to their multiple biological activities [1]. Their potential as antitumor agents arises from their ability to act on multiple cellular pathways implicated in cancer progression and to attenuate multidrug resistance (MDR) [2]. However, to overcome inherent pharmacokinetic drawbacks and target selectivity, flavones are commonly subjected to structural modifications [3]. The incorporation of chiral moieties, such as amino acids, is used to improve the pharmacokinetic parameters and selectivity [4]. Objective: This study screened a library of thirty-two new chiral flavone derivatives (CDFs) to identify promising chemotherapeutic candidates. Beyond cytotoxicity, their effects on tumor metabolism, cell death mechanisms, and their potential as P-glycoprotein (P-gp) inhibitors to overcome multidrug resistance were evaluated. Methods: Cell viability assays were performed against a panel of four human cancer cell lines: A375-C5 (melanoma), MCF-7 (breast), NCI-H460 (lung), and HCT-15 (colorectal). The most promising CDFs were further characterized with respect to their impact on metabolic profiles through the quantification of extracellular glucose and lactate levels. Additionally, apoptosis induction was evaluated by Annexin V/PI double staining and flow cytometry, while the Rhodamine 123 exclusion assay was conducted in HCT-15 cells to assess the compounds' potential as P-gp inhibitors. Results: Derivatives 6HF-DTrp and 7HF-DTrp were the most potent candidates (GI50 < 25 µM), with 7HF-DTrp displaying high specificity (SI up to 7.94) across all tumor lines. While metabolic and apoptotic responses varied by cell type, both compounds were confirmed as P-gp inhibitors through in vitro and in silico assays. Conclusions: These findings identify 6HF-DTrp and 7HF-DTrp as potent, selective, and P-gp inhibitory leads, highlighting their potential as candidates for both monotherapy and combination strategies in cancer treatment.
References
1. Pone, K. B. et al. Flavones as a privileged scaffold in drug discovery: Current developments. Curr Org Synth 2019, 16, 968–1001, doi:10.2174/1570179416666190823105432.
2. Khan, A.U. et al. Therapeutic role of flavonoids and flavones in cancer prevention: Current trends and future perspectives. Eur J Med Chem Rep 2021, 3, 100010, doi:10.1016/j.ejmcr.2021.100010.
3. Li, C. et al. Modification of flavonoids: Methods and influences on biological activities. Crit Rev Food Sci Nutr 2023, 63, 10637–10658, doi:10.1080/10408398.2022.2076135.
4. Xu, Q. et al. Application of amino acids in the structural modification of natural products: A review. Front Chem 2021, 9, 167, doi:10.3389/fchem.2021.642517.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Flávia Barbosa, Cláudia Pinto, João Machado, Andrea Cunha, Patrícia M. A. Silva, Mariangela Agamennone, Hassan Bousbaa, Honorina Cidade, Maria Elizabeth Tiritan, Odília Queirós
This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.
